{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:25:48Z","timestamp":1785889548573,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for all European registry donor transplants intended for the Australian-Pacific region. We examined properties of these transplants to ascertain how quality is maintained.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed 100 pandemic-related allogeneic mobilized blood-derived stem cell apheresis products generated at 30 collection sites throughout Europe, shipped to and cryopreserved at our center between April and November of 2020. Products were shipped in the cool, subsequently frozen with DMSO as cryoprotectant. Irrespective of origin, all products were frozen within the prescribed shelf-life of 72\u00a0h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Prior to cryopreservation, viable stem cell and leukocyte count according to the collection site and our reference laboratory were highly concordant (r<jats:sup>2<\/jats:sup>\u2009=\u20090.96 and 0.93, respectively) and viability was\u2009&gt;\u200990% in all instances. Median nominal post-thaw recovery of viable CD34+\u2009cells was 42%. Weakly associated with poorer CD34+\u2009cell recovery was higher leukocyte concentration, but not time lag between apheresis or addition of cryopreservant, respectively, and start of freezing. The correlation between pre- and post-thaw CD34+\u2009cell dose was high (r<jats:sup>2<\/jats:sup>\u2009=\u20090.85), hence predictable. Neutrophil and platelet engraftment were prompt with no evidence of dose dependency within the range of administered cell doses (1.31\u201315.56\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> CD34+\u2009cells\/kg).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>General cryopreservation of allogeneic stem cell transplants is feasible. While more than half of the CD34+\u2009cell content is lost, the remaining stem cells ensure timely engraftment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-021-02810-9","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:03:27Z","timestamp":1617883407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site"],"prefix":"10.1186","volume":"19","author":[{"given":"Eliza","family":"Wiercinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Schlipfenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-2675","authenticated-orcid":false,"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"2810_CR1","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbmt.2007.07.003","volume":"13","author":"DH Kim","year":"2007","unstructured":"Kim DH, Jamal N, Saragosa R, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transplant. 2007;13:1233\u201343.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2810_CR2","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.bbmt.2020.04.018","volume":"26","author":"M Ardura","year":"2020","unstructured":"Ardura M, Hartley D, Dandoy C, et al. Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) pandemic on hematopoietic cell transplantation: learning networks as a means for sharing best practices. Biol Blood Marrow Transplant. 2020;26:e147\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2810_CR3","unstructured":"EBMT recommendations. https:\/\/www.ebmt.org\/sites\/default\/files\/2020-06\/EBMT%20COVID-19%20guidelines%20v.9.2%20%20%282020-06-14%29.pdf. Accessed 1 Feb 2021."},{"key":"2810_CR4","unstructured":"WMDA recommendations. https:\/\/share.wmda.info\/pages\/viewpage.action?pageId=344866320#\/. Accessed 1 Feb 2021."},{"key":"2810_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10561-014-9474-5","volume":"16","author":"D Klarmann","year":"2015","unstructured":"Klarmann D, Sireis W, Hogardt M, et al. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing. Cell Tissue Bank. 2015;16:311\u20138.","journal-title":"Cell Tissue Bank"},{"key":"2810_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3109\/14653249.2010.529894","volume":"13","author":"K Dauber","year":"2011","unstructured":"Dauber K, Becker D, Odendahl M, et al. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy. 2011;13:449\u201358.","journal-title":"Cytotherapy"},{"key":"2810_CR7","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1182\/bloodadvances.2020002431","volume":"4","author":"D Purtill","year":"2020","unstructured":"Purtill D, Antonenas V, Chiappini P, et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Adv. 2020;4:4147\u201350.","journal-title":"Blood Adv"},{"key":"2810_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bmt.1704247","volume":"32","author":"H Yang","year":"2003","unstructured":"Yang H, Acker JP, Cabuhat M, McGann LE. Effects of incubation temperature and time after thawing on viability assessment of peripheral hematopoietic progenitor cells cryopreserved for transplantation. Bone Marrow Transplant. 2003;32:1021\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/bmt.2008.93","volume":"42","author":"M Lioznov","year":"2008","unstructured":"Lioznov M, Dellbrugger C, Sputtek A, et al. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant. 2008;42:121\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/sj.bmt.1703575","volume":"29","author":"DS Allan","year":"2002","unstructured":"Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:967\u201372.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/sj.bmt.1704926","volume":"35","author":"H Yang","year":"2005","unstructured":"Yang H, Acker JP, Cabuhat M, et al. Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment. Bone Marrow Transplant. 2005;35:881\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/14653240410004925","volume":"6","author":"JF Abrahamsen","year":"2004","unstructured":"Abrahamsen JF, Wentzel-Larsen T, Bruserud O. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2 \u00d7 10(6) CD34+ cells\/kg. Cytotherapy. 2004;6:356\u201362.","journal-title":"Cytotherapy"},{"key":"2810_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.transci.2013.01.017","volume":"48","author":"MV Castelhano","year":"2013","unstructured":"Castelhano MV, Reis-Alves SC, Vigorito AC, et al. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci. 2013;48:241\u20136.","journal-title":"Transfus Apher Sci"},{"key":"2810_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1089\/152581602321080619","volume":"11","author":"F DeBoer","year":"2002","unstructured":"DeBoer F, Drager AM, Pinedo HM, et al. Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts. J Hematother Stem Cell Res. 2002;11:951\u201363.","journal-title":"J Hematother Stem Cell Res"},{"key":"2810_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ajh.20707","volume":"82","author":"D Berz","year":"2007","unstructured":"Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ. Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007;82:463\u201372.","journal-title":"Am J Hematol"},{"key":"2810_CR16","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41598-019-39957-x","volume":"9","author":"J Baboo","year":"2019","unstructured":"Baboo J, Kilbride P, Delahaye M, et al. The impact of varying cooling and thawing rates on the quality of cryopreserved human peripheral blood T cells. Sci Rep. 2019;9:3417.","journal-title":"Sci Rep"},{"key":"2810_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.bmt.1705462","volume":"38","author":"NV Frey","year":"2006","unstructured":"Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the \u201ccold shoulder\u201d? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:399\u2013405.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bbmt.2020.04.001","volume":"26","author":"M Hamadani","year":"2020","unstructured":"Hamadani M, Zhang MJ, Tang XY, et al. Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2020;26:1312\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2810_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/ejh.12140","volume":"91","author":"R Parody","year":"2013","unstructured":"Parody R, Caballero D, Marquez-Malaver FJ, et al. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. Eur J Haematol. 2013;91:448\u201355.","journal-title":"Eur J Haematol"},{"key":"2810_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/bloodadvances.2020003883","volume":"5","author":"K Maurer","year":"2021","unstructured":"Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021;5:861\u201371.","journal-title":"Blood Adv"},{"key":"2810_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/bmt.2012.118","volume":"48","author":"P Medd","year":"2013","unstructured":"Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013;48:243\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2810_CR22","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1182\/blood.V85.12.3754.bloodjournal85123754","volume":"85","author":"R Haas","year":"1995","unstructured":"Haas R, Witt B, Mohle R, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood. 1995;85:3754\u201361.","journal-title":"Blood"},{"key":"2810_CR23","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1182\/blood.V83.12.3787.3787","volume":"83","author":"R Haas","year":"1994","unstructured":"Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83:3787\u201394.","journal-title":"Blood"},{"key":"2810_CR24","volume-title":"Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the COVID-19 pandemic: a national marrow donor program perspective","author":"SM Devine","year":"2020","unstructured":"Devine SM. Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the COVID-19 pandemic: a national marrow donor program perspective. Hematol: Am. J; 2020."},{"key":"2810_CR25","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.bbmt.2020.02.006","volume":"26","author":"AH Schmidt","year":"2020","unstructured":"Schmidt AH, Buk D, Platz A, den Brink MRM. Cryopreservation for all is no option in unrelated stem cell transplantation. Comment on Dholaria B, et al. securing the graft during pandemic: are we ready for cryopreservation for all? Biol Blood Marrow Transpl. 2020;26:e145\u20136.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-021-02810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:07:29Z","timestamp":1617883649000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-02810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-02810-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were extracted in a pseudonymized fashion (by charge batch number). Analyses are part of our JACIE and regulator mandated continuous product quality review. The ethics committee of Goethe University Medical Center has confirmed that these analyses are in agreement with ethical and professional regulations and no specific informed consent by donors or recipients is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.S. received support for attending meetings and\/or travel from Pfizer and Gilead, P.B. receives institutional research grants from Riemser, Medac and Neovii, holds patent and receives Royalties from Medac, is member of Speakers bureau at Novartis and Amgen and member of Advisory boards at Amgen, Novartis and Medac. H.B. receives institutional research funding from Sandoz-Hexal, receives Licensing Fees and Royalties from Medac, is a member of the Speakers Bureaus and\/or Advisory Boards of Novartis, Celgene, Boehringer Ingelheim, Miltenyi Biotech and Medac. The remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}